Total Payments
$25,053
2024 Payments
$5,438
Companies
50
Transactions
617
Medicare Patients
2,331
Medicare Billing
$430,058
Payment Breakdown by Category
Food & Beverage$9,320 (37.2%)
Consulting$8,850 (35.3%)
Research$5,517 (22.0%)
Other$850.00 (3.4%)
Education$515.46 (2.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,320 | 588 | 37.2% |
| Consulting Fee | $8,850 | 8 | 35.3% |
| Unspecified | $5,517 | 4 | 22.0% |
| Honoraria | $850.00 | 1 | 3.4% |
| Education | $515.46 | 16 | 2.1% |
Payments by Type
General
$19,536
613 transactions
Research
$5,517
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $5,580 | 32 | $0 (2024) |
| Eli Lilly and Company | $4,247 | 2 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $2,997 | 94 | $0 (2024) |
| PFIZER INC. | $2,515 | 44 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $1,802 | 99 | $0 (2024) |
| BeiGene USA, Inc. | $1,412 | 3 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $1,249 | 19 | $0 (2024) |
| Amgen Inc. | $712.70 | 44 | $0 (2024) |
| Genentech USA, Inc. | $578.76 | 46 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $535.88 | 43 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,438 | 13 | Novartis Pharmaceuticals Corporation ($1,575) |
| 2023 | $4,739 | 8 | Eli Lilly and Company ($4,225) |
| 2022 | $518.08 | 13 | E.R. Squibb & Sons, L.L.C. ($261.11) |
| 2021 | $141.11 | 6 | E.R. Squibb & Sons, L.L.C. ($117.58) |
| 2020 | $6,214 | 8 | AstraZeneca Pharmaceuticals LP ($3,910) |
| 2019 | $2,609 | 181 | E.R. Squibb & Sons, L.L.C. ($448.88) |
| 2018 | $2,832 | 200 | Novartis Pharmaceuticals Corporation ($657.58) |
| 2017 | $2,561 | 188 | E.R. Squibb & Sons, L.L.C. ($469.51) |
All Payment Transactions
617 individual payment records from CMS Open Payments — Page 3 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.18 | General |
| Category: Oncology | ||||||
| 12/19/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $5.26 | General |
| Category: Oncology | ||||||
| 12/13/2019 | Amgen Inc. | Kyprolis (Biological), XGEVA | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: Oncology | ||||||
| 12/13/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological), LENVIMA | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Education | In-kind items and services | $8.35 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2019 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $13.63 | General |
| 12/10/2019 | Kyowa Kirin, Inc. | POTELIGEO (Drug), SANCUSO | Food and Beverage | In-kind items and services | $13.43 | General |
| Category: MONOCLONAL ANTIBODY | ||||||
| 12/09/2019 | Genentech USA, Inc. | Perjeta (Biological), Kadcyla, TECENTRIQ | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: BioOncology | ||||||
| 12/06/2019 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $14.99 | General |
| 12/05/2019 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $16.60 | General |
| Category: Oncology | ||||||
| 12/02/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $10.72 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2019 | Celgene Corporation | Inrebic (Drug) | Education | In-kind items and services | $8.69 | General |
| Category: Myelofibrosis | ||||||
| 11/25/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological), LENVIMA | Food and Beverage | In-kind items and services | $12.68 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2019 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $18.09 | General |
| Category: Oncology | ||||||
| 11/21/2019 | Ipsen Biopharmaceuticals, Inc | SOMATULINE DEPOT (Drug), ONIVYDE | Food and Beverage | In-kind items and services | $16.63 | General |
| Category: Oncology/Endocrinology | ||||||
| 11/19/2019 | Daiichi Sankyo Inc. | Turalio (Drug) | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: Oncology | ||||||
| 11/18/2019 | AbbVie, Inc. | Venclexta (Drug) | Food and Beverage | In-kind items and services | $14.55 | General |
| Category: Virology | ||||||
| 11/15/2019 | Amgen Inc. | KANJINTI (Biological), Nplate, XGEVA | Food and Beverage | In-kind items and services | $22.95 | General |
| Category: Oncology | ||||||
| 11/13/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.26 | General |
| Category: Oncology | ||||||
| 11/12/2019 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $10.68 | General |
| Category: Cardiovascular | ||||||
| 11/11/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.40 | General |
| Category: Oncology | ||||||
| 11/08/2019 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $17.42 | General |
| Category: Oncology | ||||||
| 11/07/2019 | Novartis Pharmaceuticals Corporation | SANDOSTATIN LAR (Drug) | Food and Beverage | In-kind items and services | $12.23 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $10.69 | General |
| Category: Oncology | ||||||
| 11/05/2019 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug), SANDOSTATIN, VOTRIENT | Food and Beverage | In-kind items and services | $12.81 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EMBER-4: A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+ HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | Eli Lilly and Company | $4,225 | 1 |
| PALBOCICLIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
| EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | Eli Lilly and Company | $22.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 650 | 1,324 | $233,928 | $86,638 |
| 2022 | 7 | 630 | 1,521 | $247,822 | $125,691 |
| 2021 | 6 | 552 | 1,567 | $239,076 | $122,225 |
| 2020 | 7 | 499 | 1,396 | $186,028 | $95,504 |
Total Patients
2,331
Total Services
5,808
Medicare Billing
$430,058
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 142 | 426 | $61,344 | $28,101 | 45.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 72 | 206 | $56,918 | $19,821 | 34.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 71 | 148 | $27,360 | $9,102 | 33.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 145 | 235 | $23,030 | $8,889 | 38.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 30 | 65 | $23,253 | $6,119 | 26.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $9,223 | $2,882 | 31.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 26 | 27 | $7,326 | $2,737 | 37.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 23 | 40 | $6,448 | $2,682 | 41.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 15 | $6,685 | $2,078 | 31.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 17 | 17 | $3,366 | $1,498 | 44.5% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 22 | 22 | $5,610 | $1,462 | 26.1% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 13 | 15 | $1,912 | $589.70 | 30.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 26 | 46 | $1,104 | $350.06 | 31.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 25 | 39 | $349.00 | $326.48 | 93.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 252 | 770 | $110,880 | $54,731 | 49.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 85 | 147 | $31,458 | $16,598 | 52.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 53 | 192 | $28,608 | $15,270 | 53.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 29 | 121 | $23,111 | $11,831 | 51.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 36 | 42 | $12,222 | $6,232 | 51.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 39 | 39 | $10,491 | $5,513 | 52.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 81 | 117 | $11,466 | $5,491 | 47.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 18 | 38 | $10,146 | $5,305 | 52.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 15 | 15 | $4,890 | $2,337 | 47.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 27 | $2,808 | $1,480 | 52.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 11 | 13 | $1,742 | $903.43 | 51.9% |
About Dr. Jawad Francis, M.D
Dr. Jawad Francis, M.D is a Medical Oncology healthcare provider based in Altamonte Springs, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/06/2009. The National Provider Identifier (NPI) number assigned to this provider is 1407087455.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jawad Francis, M.D has received a total of $25,053 in payments from pharmaceutical and medical device companies, with $5,438 received in 2024. These payments were reported across 617 transactions from 50 companies. The most common payment nature is "Food and Beverage" ($9,320).
As a Medicare-enrolled provider, Francis has provided services to 2,331 Medicare beneficiaries, totaling 5,808 services with total Medicare billing of $430,058. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Medical Oncology
- Location Altamonte Springs, FL
- Active Since 08/06/2009
- Last Updated 12/21/2023
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1407087455
Products in Payments
- TAGRISSO (Drug) $2,937
- LUTATHERA (Drug) $1,575
- OPDIVO (Biological) $1,567
- IBRANCE (Drug) $1,418
- TEVIMBRA (Drug) $1,375
- IMFINZI (Drug) $1,186
- Nubeqa (Drug) $905.33
- IMFINZI (Biological) $557.89
- Truqap (Drug) $525.00
- KEYTRUDA (Biological) $522.75
- KISQALI (Drug) $321.53
- Revlimid (Drug) $281.78
- Xofigo (Drug) $258.82
- MEKINIST (Drug) $248.19
- XTANDI (Drug) $237.62
- Neulasta (Biological) $221.65
- Imbruvica (Drug) $195.86
- Kyprolis (Biological) $163.55
- JADENU (Drug) $153.04
- Xtandi (Drug) $144.68
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.